Huntington Bancshares Inc

Huntington's Valuation Gap Widens as Q4 Synergy Deadline Looms

Huntington Bancshares (HBAN) closed at $17.60, up 0.2%, but trades at a 14% tangible-book discount to peers. Q4 synergy execution is now the key catalyst.

Earnings 3d ago

Huntington Bancshares Falls on Weak Interest Income, Merger Doubts

Huntington Bancshares shares fell 1.1% after net interest income missed expectations, leading to a Bank of America downgrade and raising questions about merger benefits.

Markets Jul 27

Huntington Bancshares Declines 4.9% as Rising Deposit Costs Pressure Margins

Huntington Bancshares (NASDAQ:HBAN) shares dropped 4.9% this week as rising deposit costs and a declining net interest margin overshadowed solid fee income growth.

Earnings Jul 24

Huntington Bancshares Slips 5% on Deposit Cost Pressure Despite Strong Organic Growth

Huntington Bancshares shares dropped 5.1% on Thursday as rising deposit costs and a declining net interest margin overshadowed strong organic deposit growth.

Markets Jul 23

Huntington Bancshares Q2 Preview: Deal-Driven Growth Meets EPS Expectations

Huntington Bancshares (HBAN) closes up 0.6% ahead of Q2 earnings, with analysts eyeing deal-driven EPS growth amid integration costs and margin pressures.

Earnings Jul 22

Huntington Bancshares Surges on Heavy Volume, Regional Banking Outlook Brightens

Huntington Bancshares jumped 1.49% on double-average volume, outperforming regional peers. Q1 net income hit $523M, adjusted EPS 37¢, and Cadence Bank integration wraps in Q2. Management to present at Morgan Stanley June 9.

Markets May 31

Mortgage Rates Inch Lower, Affordability Squeeze Persists for Spring Buyers

U.S. mortgage rates edged down slightly, with the 30-year fixed average at 6.43%. However, purchase applications declined and the median monthly payment rose, highlighting ongoing affordability challenges.

Economy Apr 6

Huntington Bancshares Reaffirms 2026 Outlook Amid Stock Consolidation

Huntington Bancshares shares stabilized around $15.50 as management confirmed its 2026 financial guidance and projected $550 million in stock buybacks for that year, while anticipating significant cost savings from recent acquisitions.

Markets Mar 13

Huntington Bancshares Shares Rebound on 2027 EPS Outlook and Merger Synergy Details

Huntington Bancshares stock rose 0.5% Wednesday, recovering from a prior sell-off, as investors assessed its 2027 EPS target of $1.90-$1.93 and $435M in projected annual cost synergies from recent acquisitions.

Markets Feb 11

Huntington Bank Appoints Former BNY Risk Chief as CRO Amid Regulatory Shift

Huntington Bank has named Senthil Kumar, previously the top risk officer at BNY, as its new chief risk officer. The move follows the bank's entry into a stricter regulatory category after its merger with Cadence Bank pushed assets to $279 billion.

Regulation Feb 8

UniQure Holds Gains as FDA Signals Path for Huntington's Gene Therapy Filing

UniQure shares jumped 78.4% after the FDA said Phase I/II data could support an accelerated-approval filing for its Huntington's disease gene therapy AMT-130. A BLA is planned for Q3 2026.

Markets Jun 18

FDA Greenlights uniQure's Accelerated Approval Path for Huntington's Gene Therapy

uniQure shares surged 78% premarket after the FDA agreed to accept three-year Phase I/II data as the basis for an accelerated approval filing for AMT-130 in Huntington's disease, reviving the near-term U.S. path for the potential first disease-modifying treatment.

Regulation Jun 17